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Abstract
Background: Hypoxia is a hallmark of solid tumors and is associated with metastases, therapeutic resistance and
poor patient survival.
Results: In this study, we showed that hypoxia protected MDA-MB-231 breast cancer cells against paclitaxel- but
not epirubicin-induced apoptosis. The possible implication of HIF-1 and AP-1 in the hypoxia-induced anti-apoptotic
pathway was investigated by the use of specific siRNA. Specific inhibition of the expression of these two
transcription factors was shown to increase apoptosis induced by chemotherapeutic agents under hypoxia
indicating an involvement of HIF-1 and AP-1 in the anti-apoptotic effect of hypoxia. After HIF-1 specific inhibition
and using TaqMan Human Apoptosis Array, 8 potential HIF-1 target genes were identified which could take part in
this protection. Furthermore, Mcl-1 was shown to be a potential AP-1 target gene which could also participate to
the hypoxia-induced chemoresistance.
Conclusions: Altogether, these data highlight two mechanisms by which hypoxia could mediate its protective role
via the activation of two transcription factors and, consecutively, changes in gene expression encoding different
anti- and pro-apoptotic proteins.
Background
Hypoxia, a reduction in the normal level of tissue oxy-
gen tension, is well evidenced within most of solid
tumors [1]. Forty percent of all breast cancers are
reported to present hypoxic region (for a review [2])
and tumor hypoxia is often associated with resistance to
chemotherapy, immunotherapy and radiotherapy [3-5].
It is now apparent that hypoxia, according to its sever-
ity, can either promote apoptosis and cell death or con-
trariwise prevent cell death by provoking an adaptive
response leading to cell proliferation and tumor growth.
The hypoxic environment which takes place in the cen-
tre of solid tumors leads to a variety of biological
responses [6,7], the activation of the transcription factor
HIF-1 (Hypoxia Inducible Factor-1) being a major one
[8]. HIF-1 is an heterodimer composed of two subunits
belonging to the bHLH-PAS family [9], i.e. the hypoxic
response factor HIF-1a and the nuclear constitutively
expressed HIF-1b subunit, also called ARNT (aryl
hydrocarbon receptor nuclear translocator). In the pre-
sence of oxygen, HIF-1a is hydroxylated on two prolines
(residues 564 and 402) by specific oxygen prolyl hydro-
xylases (PHD). This hydroxylated form can then interact
with the von Hippel-Lindau protein (pVHL), which is
part of an E3 ubiquitin ligase complex, thus targeting
this subunit for degradation by the proteasome [10,11].
A second regulatory mechanism involves the hydroxyla-
tion of the asparagine 803 by an oxygen-dependent
asparaginyl hydroxylase (FIH-1) which prevents the
interaction between HIF-1a and its coactivators p300
and CBP [12]. Under hypoxic conditions, HIF-1a is no
longer modified, which results in its stabilization and its
translocation into the nucleus. It then dimerizes with
HIF-1b, forming the active HIF-1 transcription factor
capable of binding to the specific sequence called HRE
(hypoxia response element) present in the promoter of
its target genes [13].
Many studies demonstrate that HIF-1, activated by
hypoxia, could play an anti-apoptotic role by regulating
the expression of anti- and pro-apoptotic proteins
[14-16]. However, hypoxia was also described to play an
anti-apoptotic role by regulating expression of anti- and
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pro-apoptotic proteins independently of HIF-1 [17].
Besides HIF-1, number of other transcription factors
could be activated by hypoxic environment, among
which AP-1, already described to be implicated in the
hypoxia-induced protection against chemotherapeutic-
induced apoptosis [18].
If the mechanisms underlying the hypoxia-induced
radio- and chemoresistance begin to be described, the
actual actors of the protection still need to be identified.
The aim of this study was (i) to investigate the effect of
hypoxia on apoptosis induced by two chemotherapeutic
agents in human breast cancer MDA-MB-231 cell line
and (ii) to characterize the mechanisms underlying the
hypoxia resistance against paclitaxel-induced apoptosis
observed in these cells by investigating the putative
implication of the two transcription factors HIF-1 and
AP1.
We used the two chemotherapeutics agents paclitaxel
and epirubicin as apoptosis inducers. These two drugs
are some of the most active agents in the treatment of
breast cancer [19]. Paclitaxel, belonging to the taxane
group of chemotherapeutic agents, binds to microtu-
bules and causes their stabilization, inducing cell cycle
arrest at G2/M mitotic phase followed by apoptosis. It
also induces modulation expression or posttranslational
modification of some pro- and anti-apoptotic proteins
and regulation modification of several enzymes involved
in the regulation of apoptosis [20,21]. Epirubicin HCl,
an anthracycline analog, derivative of doxorubicin, inter-
calates into DNA strands, inhibiting DNA and RNA
synthesis. It inhibits the progression of topoisomerase II
by stabilizing DNA-topoisomerase complex, resulting in
DNA damage and induction of apoptosis [22]. It also
induces formation of reactive oxygen species promoting
apoptosis [23]. The biochemical and molecular mechan-
isms of apoptosis activation for these two drugs are
complex, affect a number of cellular pathways, and are
still under investigation.
Results
Hypoxia protects MDA-MB-231 cells against paclitaxel-
induced apoptosis
Recently, differential effects of hypoxia on drug-induced
apoptosis according to the cancer cell lines have been
reported and many studies showed that hypoxia can
confer resistance against chemotherapy-induced apopto-
sis in numerous solid tumors including breast cancer
[15,18,24]. In order to investigate the effect of hypoxia
on paclitaxel- or epirubicin-induced apoptosis, MDA-
MB-231 breast cancer cells were incubated under nor-
moxia or hypoxia with or without these two drugs and
caspase 3 activity and DNA fragmentation were assessed
(Figure 1). Hypoxia per se did not induce apoptosis
since no increase in caspase 3 activity or DNA
fragmentation were observed after 16 hours incubation.
Paclitaxel at 50 μM and epirubicin at 10 μM did trigger
apoptosis as shown by an increase in caspase 3 activity
in normoxic conditions. Hypoxia did not modify the
epirubicin-induced apoptosis. However, it markedly
inhibited the paclitaxel-increase in caspase 3 activity. An
increase in DNA fragmentation (Figure 1) as well as of
nucleus fragmentation as evidenced by DAPI staining
(data not shown), other important features of apoptotic
cells, were also observed in the presence of paclitaxel
under normoxia, which were significantly decreased by
hypoxia. The fact that epirubicin showed no DNA frag-
mentation while caspase 3 was activated may be due to
a different kinetics: caspase 3 is indeed activated before
DNA fragmentation occurs so that it may occur later
than 16 hours. In addition, in order to investigate
whether apoptosis is really involved in taxol-induced cell
death, the effect of a pan-caspase inhibitor has been stu-
died on overall cell death. Overall cell death has been
assessed by quantifying LDH release. Results showed
that zVAD-fmk did inhibit taxol- and epirubicin-
induced cell death (data not shown). This inhibition was
however partial probably because in cell culture, when
apoptosis is inhibited, cells die through necrosis, thus
also increasing LDH release. Altogether, these data
demonstrate that hypoxia is able to protect MDA-MB-
231 cells against the chemotherapeutic agent paclitaxel-
induced apoptosis.
Paclitaxel induces modifications in microtubule network
and Bim localization
In order to ensure that the hypoxia protection against
paclitaxel was not due to an inactivation of the drug in
hypoxic conditions, the paclitaxel effect on microtubules
was investigated by immunofluorescence. The localiza-
tion of the pro-apoptotic protein Bim was also studied
(Figure 2). The antimicrotubule drug paclitaxel is known
to interfere with microtubule function by binding to the
tubulin polymer and stabilizing it against depolymeriza-
tion. Figure 2 shows that on one hand neither epirubi-
cin, nor hypoxia alone influenced the network of
microtubules. On the other hand, in the presence of
paclitaxel, we observed a strong modification of the
microtubules which became shorter and thicker to form
bundles. Hypoxia did not modify this paclitaxel-induced
modification of the microtubule network. In the pre-
sence of paclitaxel, both under normoxia and hypoxia,
we also observed a redistribution of the protein Bim
from a perinuclear localization to clusters localized at
the microtubule extremities. We thus concluded that
hypoxia did not influence the effect of paclitaxel which
remains active in hypoxic conditions since microtubule
rearrangement and Bim translocation were still
observed.
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HIF-1 is involved in the hypoxia-induced protection
against paclitaxel-induced apoptosis
Recently, the influence of hypoxia in chemoresistance
has been recognized. Hypoxic conditions elicit cellular
responses designed to improve cell survival through an
adaptive process. The main transcriptional factor acti-
vated under hypoxic conditions is HIF-1 (hypoxia-indu-
cible factor-1). Regulation of gene expression through
HIF-1 (hypoxia-inducible factor-1) but also via other
transcription factors plays an important role in this pro-
cess. We investigated here whether HIF-1 could be
implicated in the hypoxia-induced protection against the
apoptosis induced by paclitaxel.
We first evaluated the stabilization of the sub-unit
HIF-1a. HIF-1 DNA binding activity as well as tran-
scriptional activity using respectively an ELISA like
TransAM assay and a reporter assay and by following
the mRNA level of the HIF-1 inducible gene LDHA.
Figure 3 shows that hypoxia induced an increase in
HIF-1a stabilization, that was lower in the presence of
paclitaxel and much higher in the presence of epirubicin
compared to the control cells (Figure 3A). DNA binding
activity of HIF-1a was increased in hypoxic conditions
and neither paclitaxel nor epirubicin influenced this
activity (Figure 3B). The transcriptional activity of HIF-1
was not modified by taxol or epirubicin under normoxic
conditions while it was increased by hypoxia alone or
combined with paclitaxel but not epirubicin. This was
directly determined by reporter assay but also indirectly
by studying gene expression of a HIF-1 inducible gene,
LDHA (Figure 3C, D). HIF-1 thus remains active in pre-
sence of paclitaxel under hypoxic conditions. It has to
be noted that under hypoxia, epirubicin inhibited HIF-1
activity while HIF-1alpha protein level was upregulated.
We hypothesized that the cell “tried” to compensate for
not having a HIF-1 active by upregulating further HIF-
1alpha level. The mechanism for this has not been stu-
died. The inhibitory effect of epirubicin on HIF-1 was
Figure 1 Effect of hypoxia on the paclitaxel or epirubicin-induced apoptosis. MDA-MB-231 cells were incubated under normoxic (N) or
hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours. (A) The caspase 3 activity was assayed by
measuring free AFC released from the cleavage of the caspase 3 specific substrate Ac-DEVD-AFC. Results are expressed in fluorescence intensity,
as mean ± 1 SD (n = 3). (B) After the incubation, DNA fragmentation was assayed using an ELISA for soluble nucleosomes (Cell Death Detection
Elisa, Roche). Results are expressed as mean ± 1 SD (n = 3). N.S. = non significantly different from control, * = significantly different from control
(p < 0.05), ** = significantly different from control (p < 0.01), *** = significantly different from control (p < 0.001); N.S. = no significant difference
between N epi and H epi, ### = significant difference between N tax and H tax (p < 0.001).
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Figure 2 Effect of hypoxia and/or paclitaxel or epirubicin on Bim protein expression. MDA-MB-231 cells were incubated under normoxic
(N) or hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours. Bim was detected by
immunofluorescence using specific Bim antibody (in green) and a-tubulin antibody was used to stain microtubules (in red). Nuclei were stained
with Topro-3 (in blue). Observation was performed in semi-quantitative confocal microscopy.
Figure 3 Analysis of HIF-1a protein expression, HIF-1 DNA binding activity, HIF-1 transcriptional activity and gene expression level of
HIF-1 inducible gene LDHA. MDA-MB-231 cells were incubated under normoxic (N) or hypoxic (H) conditions with or without paclitaxel (tax,
50 μM) or epirubicin (epi, 10 μM) for 16 hours. (A) HIF-1a was detected in total cell extracts by western blotting, using specific antibody. b-actin
was used to assess the total amount of proteins loaded on the gel. (B) After the incubation, nuclear extracts were performed and hybridized in
the ELISA well containing specific DNA probes (TransAM assay). Detection was performed using an anti-HIF-1a antibody. Results are expressed in
absorbance, as mean ± 1 SD (n = 3). (C) Cells were co-transfected with the pUAS-tk-Luc reporter plasmid encoding the firefly luciferase and the
pCMVb normalisation plasmid before incubated. Results are expressed as mean of the ratio between firefly luciferase activity and the b-
galactosidase activity ± 1 SD (n = 3). (D) After incubation, total RNA has been extracted and retro-transcribed in cDNA. A real time PCR has been
performed with specific primers for LDHA and for RPL13A, a house-keeping gene. Results are expressed in induction level by comparison with
the reference condition, normoxia. N.S. = non significantly different from control, *** = significantly different from control (p < 0.001); N.S. = no
significant difference between N epi and H epi, ### = significant difference between (1) N tax and H tax or (2) N epi and H epi (p < 0.001).
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also observed by Semenza’s team in human hepatocellu-
lar carcinoma cell line Hep3B and in human embryonic
kidney cell line HEK293 [25].
In order to study the implication of HIF-1 in the
hypoxia anti-apoptotic effect, we then used siRNA direc-
ted against the HIF-1a sub-unit. Additional file 1 shows
that a concentration of 50 nM of siRNA was high
enough to specifically inhibit the synthesis and activity
of HIF-1a but not HIF-2a while the RISC-Free control
siRNA had no effect.
Cells were transfected with anti-HIF-1a or control
siRNA before being incubated under normoxia or
hypoxia in the presence of one or the other agent. The
activity of the caspase 3 was then assessed. If HIF-1
plays an anti-apoptotic role, an increase in the pacli-
taxel-induced caspase 3 activity is expected when inhib-
ited by specific siRNA. Figure 4 shows that, on one
hand, the negative control siRNA did not influence cas-
pase 3 activity. On the other hand, this activity was
markedly increased for HIF-1a siRNA transfected cells
incubated under normoxia as well as under hypoxia,
with paclitaxel or epirubicin. No modification was
observed in control cells. The caspase 3 activity mea-
sured for HIF-1a siRNA transfected cells incubated
under hypoxia with paclitaxel reached similar level than
the activity measured for non transfected cells incubated
in normoxia with paclitaxel, indicating that the protec-
tion was reversed in this case.
These results clearly demonstrate an implication of
HIF-1 in the hypoxia-induced protection against the
apoptosis induced by paclitaxel.
HIF-1 regulates the expression of pro- and anti-apoptotic
genes
Apoptosis is a complex event controlled by numerous
pro- and anti-apoptotic genes. In order to understand
by which mean HIF-1 protects MDA-MB-231 cells
against paclitaxel-induced apoptosis, we studied the
expression of 93 genes involved in apoptosis in cells
transfected or not with HIF-1a siRNA or with control
siRNA and incubated with or without paclitaxel under
normoxic or hypoxic conditions, using Taqman Human
Apoptosis Arrays.
Gene expression data for the 77 genes detected after
real time PCR reactions are presented in additional file
2. Figure 5 shows gene expression modifications for 8 of
these genes which expression seemed to be regulated by
HIF-1 and that could be involved in the hypoxia-
induced protection against apoptosis induced by
paclitaxel.
Some of the genes are well known HIF-1 target genes
such as GAPDH and BNIP3 whose expression was
enhanced in non transfected cells or cells transfected
with control siRNA and incubated under hypoxia with
or without paclitaxel and which was inhibited by
HIF-1a siRNA. Although BNIP3 is known to play
Figure 4 Effect of HIF-1a silencing on the protective role of hypoxia on the paclitaxel-induced apoptosis. 8 h post transfection with anti-
HIF-1a siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM, 24 h), MDA-MB-231 cells were incubated under normoxic (N) or hypoxic (H)
conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours. After transfection and incubation, the caspase 3 activity
was assayed by measuring free AFC released from the cleavage of the caspase 3 specific substrate Ac-DEVD-AFC. Results are expressed in
fluorescence intensity, as mean ± 1 SD (n = 3). Statistical analysis were determined independently for the 3 subgroups without siRNA, with anti-
HIF-1a siRNA (siRNA) and with RISC-free control siRNA (RF) ; N.S. = non significantly different from control (N, N siRNA or N RF), * = significantly
different from control (p < 0.05), *** = significantly different from control (p < 0.001); N.S. (1) = no significant difference between N epi and H
epi, ### = significant difference between N tax and H tax (p < 0.001), # = significant difference between N epi and H epi (p < 0.05). N.S. = no
significant difference between (2) N tax and N tax RF or (3) H tax and H tax RF, • = significant difference between H tax and H tax siRNA (p <
0.05), ••• = significant difference between N tax and N tax siRNA (p < 0.001).
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pro-apoptotic function, a putative role in autophagy is
more recently conferred to this protein which could
thus participate to the hypoxia protection [26,27]. BAK,
CASP3, CASP8, CASP10 and TNFRSF10A are five
pro-apoptotic genes for which we observed a lower
expression under hypoxic conditions when compared to
normoxic conditions, for non-transfected cells and cells
transfected with the control siRNA. The downregulation
of these genes by hypoxia was inhibited when cells were
transfected with HIF-1a siRNA, and particularly in the
presence of paclitaxel. In this case, hypoxia alone did
not influence expression of these genes. We can there-
fore conclude that HIF-1 is responsible for the decrease
of expression of these five pro-apoptotic genes, which
could also participate to the hypoxia protection.
Hypoxia also increased the expression of the anti-
apoptotic gene MCL-1. siRNA directed against HIF-1a
inhibited this effect indicating that HIF-1 could
Figure 5 Gene expression profiling, for genes involved in regulating apoptosis, in HIF-1a silenced MDA-MB-231 cells incubated with
or without paclitaxel under normoxic or hypoxic conditions. 8 h post transfection with HIF-1a siRNA (siRNA) or RISC-free control siRNA (RF)
(50 nM, 24 h), cells were incubated under normoxic (N) or hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) for 16 hours. After
transfection and incubation, total RNA has been extracted and retro-transcribed in cDNA. TaqMan Human Apoptosis Array (Applied Biosystems)
was used to perform real time PCR for 93 human genes implicated in apoptosis in addition to three endogenous controls. 18S was used as the
house-keeping gene for data normalization. To validate results, single real-time RT-PCR reaction for BNIP3 and MCL1 were performed for
independent samples. Results are expressed in induction level by comparison with the reference condition, normoxia. Please refer to
supplementary data (Additional file 1) for results obtained for the 77 genes detected after real time PCR reactions.
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participate to the anti-apoptotic effect of hypoxia by
increasing MCL-1 expression under hypoxia in cells
incubated in the presence of paclitaxel.
In order to validate our data, we also performed single
SYBR Green quantitative real time PCR assays for two
of the selected genes (Figure 5). Good correlation
between relative transcript abundance data obtained by
micro fluidic card and by real time RT-PCR was
observed.
AP-1 is involved in the hypoxia-induced protection
against paclitaxel-induced apoptosis
The transcription factor AP-1 was also studied for its
potential role in the protection effect of hypoxia against
the paclitaxel-induced apoptosis. It was already shown
that this factor could play a role in the hypoxia-induced
anti-apoptotic effect [18]. AP-1 is composed of two pro-
teins belonging to the jun or fos family and c-jun is the
most frequent subunit. Epirubicin totally inhibited the
expression of c-jun both under normoxia and hypoxia
while paclitaxel decreased its expression, interestingly
more under normoxia than under hypoxia (Figure 6A).
The DNA binding activity of AP-1 was significantly
increased under hypoxia comparatively to normoxia
(Figure 6B). Epirubicin decreased AP-1 binding activity
both in normoxia and hypoxia while this activity was
not modified by paclitaxel. These results indicate that
hypoxia was able to increase the expression of c-jun and
DNA binding activity of AP-1 in the presence of
paclitaxel.
In order to verify a possible implication of AP-1 in the
protective role of hypoxia against paclitaxel-induced
apoptosis, c-jun siRNA was used to inhibit the expres-
sion of this transcriptional factor. Additional file 3
shows that a concentration of 50 nM of siRNA was high
enough to inhibit the synthesis and activity of c-jun
while the RISC-Free control siRNA had no effect. Cells
were transfected with c-jun or negative control siRNA
before being incubated under normoxia or hypoxia with
one or the other chemotherapeutic agent. The activity
of the caspase 3 was then assessed. Specific inhibition of
c-jun decreased the hypoxia-induced protection against
paclitaxel-induced apoptosis (Figure 7). The negative
control siRNA did not influence the caspase 3 activity
measured. On the other hand, caspase 3 activity was
markedly increased in c-jun siRNA transfected cells
incubated under normoxia or hypoxia in the presence of
paclitaxel and even more in the presence epirubicin
while it was not modified in control cells. The caspase 3
activity measured for c-jun siRNA transfected cells incu-
bated under hypoxia with paclitaxel reached a level
higher than the activity measured for non transfected
cells incubated under normoxia with paclitaxel.
AP-1 protective role is associated with Mcl-1 expression
modification
We already point out a possible role of the anti-apopto-
tic protein Mcl-1 belonging to the Bcl-2 family members
in the hypoxia protection against paclitaxel-induced
apoptosis via the activity of HIF-1. The effect of the c-
jun inhibition on Mcl-1 expression was also investigated.
Hypoxia as well as paclitaxel increased Mcl-1 expression
but epirubicin markedly decreased it both at the mRNA
and the protein levels (Figure 8). c-jun siRNA decreased
Mcl-1 mRNA expression while negative control siRNA
had no effect (Figure 9A). Similar results have been
observed for Mcl-1 protein abundance (Figure 9B).
All together, these results show that hypoxia was able
to increase the expression of c-jun and DNA binding
activity of AP-1 and that c-jun was then able to
increase Mcl-1 expression which may participate to the
Figure 6 Effect of hypoxia and/or paclitaxel or epirubicin on
the c-jun mRNA expression level and AP-1 DNA binding
activity. MDA-MB-231 cells were incubated under normoxic (N) or
hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or
epirubicin (epi, 10 μM) for 16 hours. (A) After incubation, total RNA
has been extracted and retro-transcribed in cDNA. A real time PCR
has been performed with specific primers for c-jun and for RPL13A,
a house-keeping gene. Results are expressed in induction level by
comparison with the reference condition, normoxia. (B) After the
incubation, nuclear extracts were performed and hybridized in the
ELISA well containing specific DNA probes (TransAM assay).
Detection was performed using an anti-c-jun antibody. Results are
expressed in absorbance, as mean ± 1 SD (n = 3). N.S. = non
significantly different from control, *** = significantly different from
control (p < 0.001); # = significant difference between N tax and H
tax (p < 0.01), ### = significant difference between N tax and H tax
(p < 0.001).
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Figure 7 Effect of the c-jun siRNA on the protective role of hypoxia on the paclitaxel-induced apoptosis. MDA-MB-231 cells were
incubated under normoxic (N) or hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours, 8 h post
transfection with anti-c-jun siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM, 24 h). After transfection and incubation, the caspase 3 activity
was assayed by measuring free AFC released from the cleavage of the caspase 3 specific substrate Ac-DEVD-AFC. Results are expressed in
fluorescence intensity, as mean ± 1 SD (n = 3). Statistical analysis were determined independently for the 3 subgroups without siRNA, with anti-c-
jun siRNA (siRNA) and with RISC-free control siRNA (RF) ; N.S. = non significantly different from control (N, N siRNA or N RF), ** = significantly
different from control (p < 0.01), *** = significantly different from control (p < 0.001); N.S. = no significant difference between N epi and H epi,
### = significant difference between N tax and H tax (p < 0.001), # = significant difference between (1) N epi and H epi or (2) N tax and H tax
(p < 0.05). • = significant difference between (1) N tax and N tax RF or (2) H tax and H tax RF (p < 0.05). ••• = significant difference between (1)
N tax and N tax siRNA or (2) H tax and H tax siRNA (p < 0.001),
Figure 8 Effect of hypoxia and/or paclitaxel or epirubicin on Mcl-1 mRNA expression level and protein expression. MDA-MB-231 cells
were incubated under normoxic (N) or hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours (A,
B). 8 h post transfection with c-jun siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM, 24 h), cells were incubated under normoxic condition
with or without paclitaxel (tax, 50 μM) (C). (A) After incubation, total RNA has been extracted and retro-transcribed in cDNA. A real time PCR has
been performed with specific primers for Mcl-1 and for RPL13A, a house-keeping gene. Results are expressed in induction level by comparison
with the reference condition, normoxia. (B) Mcl-1 was detected by immunofluorescence using specific Mcl-1 antibody. Nuclei were stained with
Topro-3 (in blue). Observation was performed in semi-quantitative confocal microscopy. (C) Mcl-1 was detected in total cell extracts by western
blotting, using specific antibody. a-tubulin was used to assess the total amount of proteins loaded on the gel.
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hypoxia-induced protection against apoptosis induced by
paclitaxel.
Discussion
Breast cancer cell resistance to chemotherapy is still a
great burden for patient treatment. Because of uncon-
trolled proliferation which arises during tumor growth,
distance between tumor tissue and blood vessels capable
of delivering oxygen is increased, resulting in an inade-
quate O2 supply for cells distant from the nutritive
blood vessel and inducing the establishment of hypoxic
regions [8,28]. It was recognized that cells undergo
hypoxic conditions when the distance between blood
vessels and cells exceeds the oxygen diffusion limit of
100-150 μm, [29].
Tumor hypoxia is known to enhance chemoresistance
of cancer cells by a variety of ways. The delivery of
drugs in hypoxic region could be counteracted because
of the high distance with the blood vessels [30] and cel-
lular uptake of many drugs could be affected because of
tumor associated acidity [31,32]. The lower availability
of oxygen decreases the effectiveness of drugs which
require oxygen to be active [33] and compromises oxy-
gen-dependent mechanisms such as radiotherapy
[34,35]. The decrease in cancer cell proliferation
induced by hypoxia and hypoxia-associated nutriment
deprivation also participate to resistance against the che-
motherapeutic agents which are often more effective
against proliferating cells than against quiescent cells
[32]. Hypoxia also induces cellular adaptations which
contribute to cancer progression, such as initiation of
angiogenesis and metastasis process, but also to tumor
cell chemoresistance, one of these adaptations being the
expression of multidrug resistance proteins such as ABC
transporters. Evidence of MDR-1 or MRP1 upregulation
through HIF-1 under hypoxia has been highlighted
[36,37]. Our results do not show any increase in mRNA
expression under hypoxia for these two proteins (results
not shown). Finally, hypoxia has already been described
to induce resistance to radio- and chemotherapies by
modifying gene expression [14,15,38] but the exact
mechanisms triggered by hypoxia that lead to this resis-
tance are not finely characterized, neither are the genes
involved.
MDA-MB-231 breast cancer cell line was used as in
vitro experimental model for studying the effect of
hypoxia on apoptosis induced by two commonly used
chemotherapeutic agents, i.e. paclitaxel and epirubicin
[39]. We observed that hypoxia differentially influ-
enced apoptosis in these cells according to the
chemotherapeutic agent. While in the presence of
paclitaxel at a concentration of 50 μM during 16
hours, caspase 3 activity was inhibited under hypoxic
conditions, it was not the case for epirubicin at 10 μM.
Similar results were observed when DNA fragmenta-
tion was studied.
Hypoxia in tumors causes resistance to a wide variety
of chemotherapeutic agents in many cell lines. Hypoxia
was reported to increase resistance of human pancreatic
cancer cells to gemcitabine-induced apoptosis [40], to
decrease the efficacy of many drugs including cisplatin,
etoposide, bleomycin, paclitaxel and mitomycin C in tes-
ticular germ cell tumors [41] or to mediate fenretinide
resistance in acute lymphoblastic leukaemia cells [42].
Figure 9 Effect of the c-jun siRNA on Mcl-1 expression level. (A) After transfection and incubation, total RNA has been extracted and retro-
transcribed in cDNA. A real time PCR has been performed with specific primers for Mcl-1 and for RPL13A, a house-keeping gene. Results are
expressed in induction level by comparison with the reference condition, normoxia. (B) Mcl-1 was detected in total cell extracts by western
blotting, using specific antibody. a-tubulin was used to assess the total amount of proteins loaded on the gel.
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HIF-1 being one of the main regulators of the adaptive
response to hypoxia [43], its implication in the hypoxia-
induced resistance to paclitaxel-induced apoptosis was
investigated. Indeed, although its role as an anti- or pro-
apoptotic protein is still controversy [44], many reports
have evidenced an involvement of this main transcrip-
tion factor activated by hypoxia in regulating the
hypoxic anti-apoptotic pathway. Liu et al highlighted a
contribution of HIF-1 in the hypoxia-induced chemo-
resistance against 5-FU, vincristine, cisplatine, etoposide
and adriamycin in gastric cancer cell lines [45]. HIF-1a
knockdown in breast carcinoma MCF-7 cells was shown
to elevate the sensitivity to chemotherapeutic agent
methotrexate [46] and resistance induced by hypoxia
against doxorubicin and cisplatin in non-small cell lung
cancer was reversed by silencing HIF-1a protein [47].
Down-regulation of HIF-1a by shRNA interference was
also shown to reduce hypoxia-induced resistance of neu-
roblastoma cells against etoposide and vincristine [48].
Similarly, we show here that HIF-1a silencing reverted
the hypoxia-induced protection against paclitaxel-
induced apoptosis in MDA-MB-231 cells.
We hypothesized that HIF-1 could directly induce
gene expression alterations that would influence the
paclitaxel-induced apoptosis and that would then be
responsible for the hypoxia-induced chemoresistance.
From studies performed by Daniel Stiehl from the Insti-
tute of Physiology in Zurich (personal communication),
HIF-2alpha is stabilized much later than HIF-1alpha in
breast cancer cells: while HIF-1alpha stabilization is
maximal after 4 hours, HIF-2alpha is only observed after
24 hours of hypoxia. Since the protection we observed is
well before HIF-2alpha is stabilized, we though it is
probably not involved.
Using TaqMan Human Apoptosis Array, expression
modifications of 93 genes involved in the regulation of
apoptosis were studied after HIF-1 inhibition through
RNA interference. Gene expression changes were
defined for each of them, in response to paclitaxel
under normoxic or hypoxic conditions and with or
without inhibition of HIF-1 by a siRNA approach. Gene
expression patterns were then correlated with the activ-
ity of HIF-1 in order to define molecular pathway that
could take part in hypoxia-induced chemoresistance
against paclitaxel. HIF-1 was shown to down- or up-reg-
ulate the expression of several pro- and anti-apoptotic
genes, some of them already known to be HIF-1 target.
BAK, CASP3, CASP8, CASP10 and TNFRSF10A were
identified as pro-apoptotic genes whose expression was
decreased by HIF-1 in hypoxia when compared to nor-
moxic conditions, in the presence or absence of pacli-
taxel. A decrease in BAK mRNA under hypoxia,
established to be regulated through a HIF-dependent
pathway, has already been observed by Sermeus et al in
HepG2 cells and was supposed to play a role in the pro-
tection provided by hypoxia against etoposide-induced
apoptosis [15]. TNFRSF10A (TRAIL-R1) is an apopto-
sis-inducing receptor for the tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) which is a
potent inducer of apoptosis in many cancer cells [49].
Signaling of apoptosis induced by TRAIL-R1 and its
ligand involves the formation of the DISC complex,
recruitment of FADD and pro-caspases 8 and 10, the
activation of both caspases, followed by the activation of
caspase 3 and induction of apoptosis. The consecutive
Bid cleavage, mitochondrial depolarization, cytochrome
c release and activation of caspase 9 could drive apopto-
sis through a mitochondrial pathway [50]. Correlation
between the expression of the receptor and tumor pro-
gression seemed to be tumor type specific [51]. Over-
expression of TRAIL-R1 was shown to efficiently killed
MDA-MB-231 cells and other cancer cell lines even in
the absence of exogenous TRAIL [52]. Hence, the
decrease in TRAIL-R1 expression observed under
hypoxia may participate to the hypoxia-induced
protection.
HIF-1 was also shown to increase the expression of
Mcl-1 and BNIP-3. Mcl-1 (myeloid cell leukaemia
sequence 1) is an anti-apoptotic protein belonging to the
Bcl-2 family. It is known to promote cell survival through
suppression of cytochrome c release from mitochondria
via heterodimerization and neutralization of pro-apopto-
tic proteins such as Bim or Bax [53]. Increased levels of
Mcl-1 have been reported in a variety of human tumors,
where elevated expression is associated with disease
recurrence and drug resistance (for a review [54], sug-
gesting an important role played by Mcl-1 in cancer cell
survival. Previous studies also demonstrated that Mcl-1
overexpression could be regulated by HIF-1 [55] and
could protect hepatoma HepG2 cells against tert-butyl
hydroperoxide-induced apoptosis [14]. BNIP3, known as
a proapoptotic member of the Bcl-2 family of cell death
factors, was shown to be regulated by HIF-1 [56] and
overexpressed in human tumors [57]. However a putative
role in autophagy is more recently conferred to this pro-
tein which could thus participate to the hypoxia protec-
tion. It appears that in hypoxia, HIF-1 induces the
expression of BNIP3 which triggers selective mitochon-
drial autophagy. This event represents an adaptive meta-
bolic response to hypoxia to maintain redox homeostasis
and to prevent cell death. [26,27].
From these results, we concluded that one putative
mechanism by which hypoxia opposes to the paclitaxel-
induced apoptosis could be through the regulation of
the expression of some pro- and anti-apoptotic through
a HIF-dependent pathway.
The transcription factor AP-1 has already been shown
to be activated in cells exposed to hypoxic conditions
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and is known to be involved in regulation of apoptosis
[58]. We then decided to investigate, in the second part
of the work, the potential role of this factor in the pro-
tection effect of hypoxia against apoptosis induced by
paclitaxel. AP-1 has already been shown to participate
in hypoxia protection against etoposide-induced apopto-
sis in HepG2 cells [18]. Many publications describe cell
lines in which c-jun was inhibited by various strategies,
resulting in enhanced sensitivity to a panel of DNA-
damaging drugs (for a review [59]. c-jun overexpression,
followed by c-jun phosphorylation and AP-1 activation,
in response to microtubule inhibitor vinblastine, was
also shown to render MCF7 breast cancer cells mark-
edly resistant to this drug [60].
We evidenced that hypoxia increased AP-1 DNA-
binding activity and expression of c-jun in the presence
of paclitaxel and that inhibition of c-jun reversed the
protective effect of hypoxia against apoptosis induced by
paclitaxel. c-jun was also shown to increase mRNA
expression of the anti-apoptotic protein Mcl-1 which
may participate to this protection.
These results suggest a potential anti-apoptotic role of
AP-1 which could protect cells against paclitaxel-
induced apoptosis under hypoxia and that AP-1-
mediated overexpression of Mcl-1 may participate to
this protection.
In conclusion, our data suggest an inhibition of the
paclitaxel-induced apoptosis by hypoxia through activa-
tion of the two transcriptional factors HIF-1 and AP-1.
Activation of these two factors leads to the overexpres-
sion or repression of various pro- and anti-apoptotic
genes respectively. Our results provide two possible
mechanisms for the induction of chemoresistance under
hypoxia in MDA-MB-231breast cancer cell line. It does
not exclude that hypoxia exerts its effect via other
mechanisms and additional studies are now needed to
evaluate the exact implication of the proteins we
pointed out. Identification of proteins involved in che-
moresistance is crucial in order to design new therapeu-
tics aimed at ameliorating breast cancer patient
treatment.
Methods
Cell culture and hypoxia incubation
Human Breast Cancer cells MDA-MB-231 were main-
tained in culture in 75-cm2 polystyrene flasks (Costar)
with 15 ml of Roswell Park Memorial Institute medium
(RPMI 1640, Invitrogen) containing 10% of fetal calf
serum (Invitrogen) and incubated under an atmosphere
containing 5% CO2.
For hypoxia experiments (1% O2), cells were incubated
in serum-free CO2-independent medium (Invitrogen)
supplemented with 1 mM L-glutamine (Sigma) with or
without paclitaxel (Invitrogen) at 50 μM or epirubicin
(Calbiochem) at 10 μM. Normoxic control cells were
incubated in the same conditions but in normal atmo-
sphere (20% O2).
siRNA transfection
Silencing of HIF-1a or c-jun expression was achieved
using siGENOME SMARTpool human HIF1A/c-jun
from Dharmacon. RISC-free control siRNA purchased
from Dharmacon was used to control for non-specific
effects. For siRNA experiments, 2 × 106 cells were seeded
in 75-cm2 polystyrene flasks (Costar) with 10 ml of RPMI
1640 medium (RPMI) containing 10% of fetal calf serum
and incubated 24 hours under an atmosphere containing
5% CO2. Cells were then transfected 24 hours under
standard culture conditions with 50 nM siRNA using the
DharmaFECT 1 (Dharmacon) transfection reagent
according to the manufacturer’s instructions.
The transfection media were removed and replaced by
culture media for 8 hours. Cells were then trypsinized
and seeded at the appropriate density in flasks or micro-
plates, depending on the experiment to perform.
Caspase 3 activity
The fluorogenic substrate Ac-DEVD-AFC was used to
measure caspase 3 activity according to Lozano et al [61].
Cell extracts were prepared as described by Wellington
et al [62]. Cells were seeded in 6-well plates (300,000
cells/well) one day before the incubation. After the incu-
bation, the medium was recovered and centrifuged at
1,000 g for 5 min. Cells still attached to the well were
scrapped in 200 μl cold PBS and recovered into a micro-
tube. Pelleted cells were resuspended in 100 μl PBS at
4°C and also added to the microtube. The samples were
centrifuged at 1,000 g for 5 min. at 4°C and the pellet
resuspended in 50 μl of lysis buffer (10 mM Hepes/KOH,
pH 7.0, 10% sucrose, 2 mM EDTA, 0.1% CHAPS, 5 mM
dithiothreitol and 10 μg/ml aprotinin). After incubation
at 4°C on a rotating wheel for 15 min, the lysates were
centrifuged at 13,000 g for 5 min at 4°C and the superna-
tants were recovered for the assay.
The protein concentration was measured and 10 μg
proteins completed to 50 μl with lysis buffer were mixed
with 13 μM Ac-DEVD-AFC (BD Pharmingen) and 50 μl
reaction buffer (40 mM PIPES, pH 7.2, 200 mM NaCl, 2
mM EDTA, 0.2% CHAPS, 0.10% sucrose and 10 mM
dithiothreitol). The reaction was allowed to take place
for 1 hour at 37°C and the fluorescence generated by
the release of the fluorogenic group AFC on cleavage by
caspase 3 was measured by excitation at 400 nm and
emission at 505 nm.
DNA fragmentation
The measurement of cytoplasmic histone-associated
DNA fragments (mono- and oligonucleosomes) after
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induction of cell death was performed with the «cell
death detection ELISA» (Roche Molecular Biochem-
icals). After treatment, cells were lysed with the incuba-
tion buffer and the cytoplasmic fraction recovered.
ELISA was performed according to the manufacturer’s
protocol.
Immunofluorescence staining and confocal microscopy
MDA-MB-231 cells were seeded at 30,000 cells/well in
24-well plates and 24 hours later were incubated for
16 hours with or without paclitaxel or epirubicin under
normoxic or hypoxic conditions. Immunofluorescence
staining was performed as described in [18].
Primary antibody for Bim staining was rabbit anti-Bim
(# 2819 Cell Signaling) (1/100 dilution). Primary anti-
body for Mcl1 staining was rabbit anti-Mcl1 (# 819
Santa Cruz) (1/100 dilution). Alexa Fluor-488-conju-
gated anti rabbit IgG antibody (Molecular Probes) was
used at 1/1,000 dilution. Primary antibody for a-tubulin
staining was mouse anti-a-tubulin (# T5186 Sigma) (1/
100 dilution). Alexa Fluor-546-conjugated anti-mouse
IgG antibody (Molecular Probes) was used at 1/1,000
dilution.
Western blotting
Cells, seeded and incubated in 25 cm2 flasks, were
scrapped in 200 μl of lysis buffer (Tris 40 mM pH 7.5,
KCl 150 mM, EDTA 1 mM, triton X-100 1%) contain-
ing a protease inhibitor mixture («Complete» from
Roche Molecular Biochemicals, 1 tablet in 2 ml H2O,
added at a 1/25 dilution) and phosphatase inhibitors
(NaVO3 25 mM, p-Nitrophenyl Phosphate (PNPP) 250
mM, b-glycerophosphate 250 mM and NaF 125 mM,
at a 1/25 dilution). Western blot analysis was per-
formed as described in [18] using mouse anti-HIF-1a
antibody (# 610958 Becton Dickinson) used at 1/1,500
dilution or rabbit anti-MCL1 antibody (# 4572 Cell
Signaling) used at 1/5000 dilution. Mouse anti-b-actin
antibody (A5441 Sigma) (final dilution 1/100,000) and
mouse anti-a-tubulin (Sigma) (final dilution 1/3000)
were used for normalization. Mouse and rabbit IgG
horseradish peroxidase-linked antibody (Amersham
Pharmacia Biotech) was used at 1/300,000 dilution as
secondary antibodies.
Nuclear protein extraction
Nuclear protein extractions in high salt buffer were
prepared as previously described [63]. Briefly, cells
seeded in 75 cm2 flasks (Corning) were incubated with
or without paclitaxel at 50 μM or epirubicin at 10 μM
under normoxic or hypoxic conditions for 16 hours.
At the end of the incubation, cells were rinsed with
PBS containing 1 mM Na2MoO4 and 5 mM NaF. They
were then incubated on ice for 3 minutes with 10 ml
cold Hypotonic Buffer (HB 1X, 20 mM HEPES, 5 mM
NaF, 1 mM Na2MoO4, 0.1 mM EDTA) and harvested
in 500 μl HB containing 0.5% NP-40 (Sigma). Cell
lysates were centrifuged 1 minute at 13,000 rpm and
sedimented nuclei were resuspended in 50 μl HB con-
taining 20% glycerol and a protease inhibitor cocktail
(Roche) and phosphatase inhibitors (1 mM Na3VO4,
5 mM NaF, 10 mM p-nitrophenylphosphate, 10 mM
b-glycerophosphate). Extraction was performed for
30 minutes at 4°C by the addition of 50 μl HB
containing 20% glycerol, 0.8 M NaCl and protease/
phosphatase inhibitors. Nuclear extracts from the
supernatant were recovered after centrifugation for
10 minutes at 13,000 rpm.
DNA-binding assay
DNA-binding assays using TransAM ELISA kit (Active
Motif) for detecting transcription factor DNA binding
activity was performed according to the manufacturer’s
recommendations. Briefly, 5 μg of nuclear proteins were
incubated for 1 hour in a 96-well plate coated with a
double-stranded oligonucleotide containing the consen-
sus sequence recognized by the transcription factor to
be assayed. The transcription factor bound to DNA was
detected using a specific primary antibody (rabbit anti-
c-Jun (SC-1964 Santa Cruz), mouse anti-HIF-1a
(H72320 Transduction Laboratories)). Colorimetric reac-
tion was then performed with a HRP-conjugated anti-
rabbit or anti-mouse IgG antibody and absorbance was
measured at 450 nm in a spectrophotometer.
Transient transfection and luciferase assay
MDA-MB-231 transfections were performed in 24-well
plates (35,000 cells per well) with SuperFect reagent
(Qiagen). 1384 ng of the reporter plasmid pGL3(PGK-
HRE6)-tk-Luc containing binding sites for HIF-1
upstream of the firefly luciferase gene [64] were co-
transfected with 115.4 ng of normalization vector
(pCMVb vector coding for the b-galactosidase, Pro-
mega) in RMPI without serum for 5 hours.
The transfection media were removed and replaced by
culture media for 24 hours. Cells were then incubated
under hypoxia for 16 hours. After hypoxia incubation,
b-galactosidase was assayed in parallel to the firefly luci-
ferase activity, assayed in a luminometer using the Luci-
ferase Reporter Assay System (Promega). Results are
expressed as means of the ratio between the firefly luci-
ferase activity and the b-galactosidase activity.
Real time RT-PCR
After the incubation, total RNA was extracted using the
Total RNAgent extraction kit (Promega). mRNA con-
tained in 2 μg total RNA was reverse transcribed using
SuperScript II Reverse Transcriptase (InVitrogen) and
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oligodT primers according to the manufacturer’s
instructions. Forward and reverse primers for RPL13A,
C-JUN, MCL-1, LDHA, BNIP3 and TNFRSF1B were
designed using the Primer Express 1.5 software (Applied
Biosystems). Amplification reaction assays contained 1×
SYBR Green PCR Mastermix (Applied Biosystems) and
primers (Applied Biosystems) at the optimal concentra-
tions. A hot start at 95°C for 5 minutes was followed by
40 cycles at 95°C for 15 seconds and 65°C for 1 minute
using an ABI PRISM 7000 SDS thermal cycler (Applied
Biosystems). RPL13A was used as the reference gene for
normalization and mRNA expression level was quanti-
fied using the threshold cycle method.
Taqman Low Density Array
After the incubation, total RNA was extracted using the
Total RNAgent extraction kit (Promega). mRNA con-
tained in 2 μg total RNA was reverse transcribed using
the “High Capacity cDNA Archive” kit from Applied
Biosystems according to the manufacturer’s instructions.
100 ng of retrotranscribed total RNA in 50 μl were then
mixed with 50 μl of the “Taqman Universal PCR master
Mix” (Applied Biosystems) and loaded into one of the 8
fill ports the microfluidic array. “TaqMan Human Apop-
tosis Arrays” are 384-well micro fluidic cards that con-
tain assays for 93 human genes in addition to 3
endogenous controls. They enable to perform 96 real-
time PCR reactions simultaneously for 4 samples, allow-
ing the detection of 96 genes. mRNA expression level
was quantified using the threshold cycle method with
18S as the reference gene.
Statistics
SigmaStat software (Jandle Scientific, Germany) was
used for the statistical analysis. Data are presented as
means ± SD and were evaluated by one-way ANOVA,
using the Holm-Sidak method.
Additional material
Additional file 1: Effect of HIF-1a silencing on HIF-1a, Bnip3 and
HIF-2a expression. (A) MDA-MB-231 cells were transfected 24 h with
anti-HIF-1a siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM). The
transfection media were removed and replaced by culture media for 24
or 48 hours. Cells were then incubated under normoxic (N) or hypoxic
(H) conditions for 16 hours. After transfection and incubation, HIF-1a was
detected in total cell extracts by western blotting, using specific
antibody. a-tubulin was used to assess the total amount of proteins
loaded on the gel. (B) MDA-MB-231 cells were transfected 24 h with anti-
HIF-1a siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM). The
transfection media were removed and replaced by culture media for 24.
Cells were then incubated under hypoxic (H) conditions for 16 hours.
After transfection and incubation, total RNA has been extracted and
retro-transcribed in cDNA. A real time PCR has been performed with
specific primers for HIF-1a, Bnip3, HIF-2a and for RPL13A, a house-
keeping gene. Results are expressed in induction level by comparison
with the reference condition, hypoxia.
Additional file 2: Gene expression profiling, for genes involved in
regulating apoptosis. MDA-MB-231 cells were transfected or not with
HIF-1a siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM, 24 h) and
were incubated with or without paclitaxel (tax) under normoxic (N) or
hypoxic (H) conditions. TaqMan Human Apoptosis Array (Applied
Biosystems) was used to perform real time PCR for 93 human genes
implicated in apoptosis in addition to three endogenous controls. 18S
was used as the house-keeping gene for data normalization. Results
obtained for the 77 genes detected after real time PCR reactions are
expressed in induction level by comparison with the reference condition,
normoxia (RQ) and cycle threshold (Ct) are given.
Additional file 3: Effect of c-jun silencing on c-jun expression. MDA-
MB-231 cells were transfected 24 h with c-jun siRNA (siRNA) or RISC-free
control siRNA (RF) (50 nM). Cells were then incubated with or without
paclitaxel (tax, 50 μM) under normoxic (N) conditions for 16 hours. After
transfection and incubation, total RNA has been extracted and retro-
transcribed in cDNA. A real time PCR has been performed with specific
primers for C-JUN and for RPL13A, a house-keeping gene. Results are
expressed in induction level by comparison with the reference condition,
normoxia.
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